Enzymes and biosolutions

“Business Segments The Human Health Ingredients (HHI) segment is dedicated to developing and supplying krill and algea-based ingredients for dietary supplements and functional foods. The product portfolio includes Superba Krill Oil, a phospholipid-bound omega-3 supplement supporting heart, brain, and joint health; Lysoveta, a lysophosphatidylcholine (LPC) molecule designed to enhance omega-3 transport to the brain and eyes; Revervia, a new plant-based, marine source of DHA omega-3 oil from algae and PL+, a highconcentration phospholipid extract with specialized nutritional applications.”

Annual report 2024A · The company itself

“ABT leverer nyskapende, naturlige virkestoffer til kosmetikkprodusenter, med egenutviklede ingredienser som Aquabeautine XL®, Chaga og Spirulysat®. • Logistikk.”

Annual report 2024A · The company itself

“Selskapets egenutviklede og patenterte teknologi er basert på enzymer og proteiner som finnes naturlig i klekkevæske fra bla. laks. ABTs første og viktigste produkt var Aquabeautine XL®, som kombinerer flere av de dokumenterte effektene som enzymene og proteinene i laksens klekkevæske har på huden.”

Annual report 2024A · The company itself

“Innovation remains a cornerstone of our strategy. The ADEPT project is driving the development of our first mRNA enzymes, and we will continue to expand our molecular tools offerings with new amplification and sample preparation solutions.”

Annual report 2024A · The company itself

“ArcticZymes AS Product Offering ArcticZymes enzymes are primarily derived from cold-water marine species and organisms from other environments. Each enzyme or product offers novel functionality and other benefits to its customers. Products offered include: utilisation in clean-up prior to Sanger sequencing and NGS (Next Generation Sequencing) processes.”

Annual report 2024A · The company itself

“Shrimp Alkaline Phosphatase (SAP) – For The Company is creating value from innovative enzyme technologies which capitalises on more than three decades of world-class research at the Arctic University of Tromsø and collaborations with national and international partners to offer niche and highquality life science products. utilised for enzymatic clean-up in Sanger Sequencing processes globally. ArcticZymes Technologies’ products and capabilities are protected via a large portfolio of patents and 20+ years of know-how in innovating and manufacturing enzymes. contaminating dU-DNA providing assurance to avoid false positives tests.”

Annual report 2024A · The company itself

“Board of Directors’ Report 2024 8 Other technology areas ArcticZymes serves through its enzymes include: • Synthetic Biology - a multidisciplinary area engaged in creating new biological parts, devices, systems relying on a plethora of molecular biology techniques. ArcticZymes’ ligase prototypes, polymerases, and pipeline innovations, including DNA assembly, show great promise for future utility in this market. • Liquid Biopsies – DNA or other diagnostics tests are performed on blood or other body fluids.”

Annual report 2024A · The company itself

“The Company received a 12 MNOK grant from the Research council of Norway to develop new innovative mRNA enzymes. A consortium has been established together with SINTEF and the University of Tromsø with the aim of developing new enzymatic technologies that can aid the manufacturing of mRNA based therapeutics. The project runs over three years and 2.5 MNOK was expensed on this project in 2024.”

Annual report 2024A · The company itself

“Ted Fjällman, VD 5 VD-ORD ”Genom börsnoteringen kan Flerie nu erbjuda exponering och likviditet i en portfölj av privata, innovativa life sciencebolag” Ett annat bolag inom mikrobiell terapi, Microbiotica, Sist men inte minst vill jag understryka att vi som life ligger inte långt efter och har påbörjat två kliniska science-investerare sticker ut i vårt engagemang för att prövningar för att behandla melanom och ulcerös kolit. även utveckla teknologier som stödjer övergången till Proteinkinashämmare (PKI) ligger i framkant när det en grönare framtid. Vi har exponering mot flera sådana gäller att behandla en mängd olika cancersjukdomar. verksamheter genom vår investering i fonden Alder, Även om marknadslanseringen av bolagets första men jag vill särskilt lyfta fram att vårt aktiva ägande i produkt, Dasynoc, försenades, gjorde Xspray Pharma Chromafora belönades genom en finansiering på 22,5 framsteg i alla sina program och tillkännagav en fjärde miljoner euro från Europeiska Investeringsbanken.”

Annual report 2024A · The company itself

“Grenar, toppar, bark och sågspån blir förnybar bioenergi som kan användas för att producera el, värme och biodrivmedel.”

Annual report 2024A · The company itself

“Health & Biosciences Our Health & Biosciences segment consists of the development and production of an advanced biotechnology-derived portfolio of enzymes, food cultures, probiotics and specialty ingredients for food and non-food applications. Among many other applications, our portfolio includes cultures for use in fermented foods such as yogurt, cheese and fermented beverages, probiotic strains, household detergents, animal feed, ethanol production and brewing.”

Annual report 2025A · The company itself

“KPIs relating to marine resources include origin of fish meal and fish oil, the percentage of fish meal and fish oil which is sustainably certified, percentage of trimmings used, recaptured fish-in-fish-out (FIFO; explained hereafter), and inclusion of emerging feed raw materials. Since the Fish in-Fish out concept first arose in the 2000s, technological improvements have been implemented across the entire fish meal/fish oil (FM/FO) value-chain. The recapture of FM/ FO from farmed fish takes this process a step further; we call this the Recapture FIFO (rFIFO), a metric that more accurately reflects the ‘net’ use of FM/FO.”

Annual report 2024A · The company itself

“Enzymes Proteins Cultures Probiotics Yeast Human milk oligosaccharides (HMOs)”

Annual report 2025A · The company itself

“We are a pure biology player with deep scientific expertise in microbiology and industrial fermentation. Our biosolutions are used in a broad range of industries from food and nutrition to agriculture, household care and energy.”

Annual report 2025A · The company itself

“For the years ended December 31, 2025 and 2024, Sanofi collaboration revenue (most of which is attributable to our share of profits from the commercialization of Dupixent) represented 41% and 32% of our total revenues, respectively.”

Annual report 2025A · The company itself

“Our products include pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators.”

Annual report 2026A · The company itself

“The manufacturing processes for biologics and cell and genetic therapies are more complex than those required for small molecule drugs and require different systems, equipment, facilities, and expertise. Additionally, we are unable to utilize a single process for all of our biologics and cell and genetic therapies; they must be customized for each program and therapy. We are investing and plan to continue to invest significant resources in expanding and strengthening our manufacturing infrastructure and capabilities, such as current Good Manufacturing Practices (“cGMP”) clinical manufacturing, both independently and through third-party networks, in an effort to develop and commercialize our biologics and cell and genetic therapies.”

Annual report 2025A · The company itself

“Hallituksen toimintakertomus Tilinpäätös Muut 24 Paikallisilta markkinoilta ostettavien, laatuvaatimukset täyttävien polttoaineiden, kuten esimerkiksi biopolttoaineiden osalta, saatavuus on merkittävämpi riski, sillä toimittajia voi olla rajallinen määrä.”

Annual report 2025A · The company itself